# Omeros Corp (OMER)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/omeros-corp/ JSON: https://steadybase.io/company/omeros-corp.json Checked Nov 10, 2026. Latest filing read: Aug 13, 2026.

## Company

- Legal name: OMEROS CORP
- Ticker: OMER (Nasdaq)
- SEC CIK: 0001285819
- Industry: Pharmaceutical Preparations (SIC 2834)
- Headquarters: Seattle, WA
- Fiscal year ends: December 31
- SEC filer category: Non-accelerated filer<br>Smaller reporting company
- Website: omeros.com
- LinkedIn: https://www.linkedin.com/company/omeros-corporation
- Next earnings date: Nov 12, 2026

## Key facts

- Revenue: $73.8M for the fiscal year ended Dec 31, 2020 (10-K filed Mar 1, 2021). Source: https://www.sec.gov/Archives/edgar/data/1285819/000155837021002177/0001558370-21-002177-index.html
- Operating income: -$122.8M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 31, 2026). Source: https://www.sec.gov/Archives/edgar/data/1285819/000143774926010636/0001437749-26-010636-index.html
- Net income: -$3.4M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 31, 2026). Source: https://www.sec.gov/Archives/edgar/data/1285819/000143774926010636/0001437749-26-010636-index.html
- SG&A: $41.5M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 31, 2026). Source: https://www.sec.gov/Archives/edgar/data/1285819/000143774926010636/0001437749-26-010636-index.html
- Employees: 175 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1285819/000143774926010636/omer20251231_10k.htm
- Shares outstanding: 72,388,316 as of Aug 7, 2026 (10-Q filed Aug 12, 2026). Source: https://www.sec.gov/Archives/edgar/data/1285819/000143774926027318/0001437749-26-027318-index.html
- Auditor: Ernst & Young LLP, Seattle, Washington, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1285819/000143774926010636/omer20251231_10k.htm

## Business

Omeros Corporation (“Omeros,” the “Company” or “we”) is an innovative, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1285819/000143774926010636/omer20251231_10k.htm

## Officers and directors

- Gregory A. Demopulos MD, Chairman, CEO & President. LinkedIn: https://linkedin.com/in/greg-demopulos-4491a01. Source: Form 4 filed Jul 24, 2026, https://www.sec.gov/Archives/edgar/data/1285819/000143774926024443/0001437749-26-024443-index.htm
- Peter B. Cancelmo, VP, General Counsel. LinkedIn: https://linkedin.com/in/cancelmo. Source: Form 4 filed Sep 1, 2026, https://www.sec.gov/Archives/edgar/data/1285819/000143774926029427/0001437749-26-029427-index.htm
- Andreas Grauer, M.D., chief medical officer. Source: 10-K filed Mar 31, 2026, https://www.sec.gov/Archives/edgar/data/1285819/000143774926010636/omer20251231_10k.htm
- David W. Ghesquiere, chief business development officer. Source: 10-K filed Mar 31, 2026, https://www.sec.gov/Archives/edgar/data/1285819/000143774926010636/omer20251231_10k.htm
- Nadia Dac, chief commercial officer. Source: 10-K filed Mar 31, 2026, https://www.sec.gov/Archives/edgar/data/1285819/000143774926010636/omer20251231_10k.htm
- Peter B. Cancelmo, J.D., vice president, general counsel and secretary. Source: 10-K filed Mar 31, 2026, https://www.sec.gov/Archives/edgar/data/1285819/000143774926010636/omer20251231_10k.htm
- J. Steven Whitaker, M.D., J.D., vice president, clinical development. Source: 10-K filed Mar 31, 2026, https://www.sec.gov/Archives/edgar/data/1285819/000143774926010636/omer20251231_10k.htm
- Mariana N. Dimitrova, Ph.D., vice president, chemistry, manufacturing, and controls (“CMC”). Source: 10-K filed Mar 31, 2026, https://www.sec.gov/Archives/edgar/data/1285819/000143774926010636/omer20251231_10k.htm
- Peter W. Williams, vice president, human resources. Source: 10-K filed Mar 31, 2026, https://www.sec.gov/Archives/edgar/data/1285819/000143774926010636/omer20251231_10k.htm
- David J. Borges, VP, Finance & CAO. LinkedIn: https://www.linkedin.com/in/davidborges1. Source: Form 4 filed Sep 24, 2026, https://www.sec.gov/Archives/edgar/data/1285819/000143774926031169/0001437749-26-031169-index.htm
- Joseph Schocken, director. Source: 8-K filed Aug 13, 2026, https://www.sec.gov/Archives/edgar/data/1285819/000155278126000441/e26350_omer-8k.htm
- Arnold C. Hanish, Board member (per proxy). Source: DEF 14A filed Apr 30, 2026, https://www.sec.gov/Archives/edgar/data/1285819/000155278126000281/e26114_omer-def14a.htm
- Diana T. Perkinson, M.D., Board member (per proxy). Source: DEF 14A filed Apr 30, 2026, https://www.sec.gov/Archives/edgar/data/1285819/000155278126000281/e26114_omer-def14a.htm
- Peter A. Demopulos, M.D., Board member (per proxy). Source: DEF 14A filed Apr 30, 2026, https://www.sec.gov/Archives/edgar/data/1285819/000155278126000281/e26114_omer-def14a.htm
- Rajiv Shah, M.D., Board member (per proxy). Source: DEF 14A filed Apr 30, 2026, https://www.sec.gov/Archives/edgar/data/1285819/000155278126000281/e26114_omer-def14a.htm
- Thomas F. Bumol, Ph.D., Board member (per proxy). Source: DEF 14A filed Apr 30, 2026, https://www.sec.gov/Archives/edgar/data/1285819/000155278126000281/e26114_omer-def14a.htm
- Thomas J. Cable, Board member (per proxy). Source: DEF 14A filed Apr 30, 2026, https://www.sec.gov/Archives/edgar/data/1285819/000155278126000281/e26114_omer-def14a.htm

## Recent 8-K events

- Oct 30, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1285819/000155278126000531/e26432_omer-8k.htm
- Aug 13, 2026: Item 5.02, Departure or appointment of directors or officers; compensation. Source: https://www.sec.gov/Archives/edgar/data/1285819/000155278126000441/e26350_omer-8k.htm
- Aug 12, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1285819/000143774926027313/omer20260521_8k.htm
- Jul 20, 2026: Item 8.01, Other events. Source: https://www.sec.gov/Archives/edgar/data/1285819/000143774926023886/omer20260716_8k.htm
- Jul 6, 2026: Item 8.01, Other events. Source: https://www.sec.gov/Archives/edgar/data/1285819/000155278126000377/e26295_omer-8k.htm
- Jun 25, 2026: Item 5.07, Submission of matters to a vote of security holders. Source: https://www.sec.gov/Archives/edgar/data/1285819/000143774926021617/omer20260613_8k.htm
- Jun 18, 2026: Item 8.01, Other events. Source: https://www.sec.gov/Archives/edgar/data/1285819/000143774926021040/omer20260618_8k.htm
- May 13, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1285819/000143774926016718/omer20260403_8k.htm
- Mar 31, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1285819/000143774926010634/omer20251116_8k.htm
- Jan 7, 2026: Item 2.02, Results of operations and financial condition (earnings release). Source: https://www.sec.gov/Archives/edgar/data/1285819/000143774926000820/omer20260107_8k.htm

## Insider trades (Form 4)

- Sep 23, 2026: David J. Borges (VP, Finance & CAO) sold 20,000 shares, about $419,000. Source: https://www.sec.gov/Archives/edgar/data/1285819/000143774926031169/0001437749-26-031169-index.htm
- Aug 31, 2026: Peter B. Cancelmo (VP, General Counsel) sold 50,000 shares, about $929,750. Source: https://www.sec.gov/Archives/edgar/data/1285819/000143774926029427/0001437749-26-029427-index.htm
- Aug 27, 2026: Arnold C. Hanish (Director) sold 15,000 shares, about $282,150. Source: https://www.sec.gov/Archives/edgar/data/1285819/000143774926029191/0001437749-26-029191-index.htm
- Aug 24, 2026: David J. Borges (VP, Finance & CAO) sold 10,906 shares, about $206,805. Source: https://www.sec.gov/Archives/edgar/data/1285819/000143774926028951/0001437749-26-028951-index.htm
- Aug 20, 2026: Thomas J. Cable (Director) sold 15,000 shares, about $276,750. Source: https://www.sec.gov/Archives/edgar/data/1285819/000143774926028754/0001437749-26-028754-index.htm
- Aug 13, 2026: David J. Borges (VP, Finance & CAO) sold 5,000 shares, about $84,750. Source: https://www.sec.gov/Archives/edgar/data/1285819/000143774926028229/0001437749-26-028229-index.htm
- May 22, 2026: Thomas J. Cable (Director) sold 7,500 shares, about $87,075. Source: https://www.sec.gov/Archives/edgar/data/1285819/000143774926018625/0001437749-26-018625-index.htm
- Jan 13, 2026: David J. Borges (VP, Finance & CAO) sold 60,000 shares, about $750,900. Source: https://www.sec.gov/Archives/edgar/data/1285819/000143774926001280/0001437749-26-001280-index.htm

## Latest filings

- 8-K filed Oct 30, 2026: https://www.sec.gov/Archives/edgar/data/1285819/000155278126000531/e26432_omer-8k.htm
- 10-K filed Mar 31, 2026: https://www.sec.gov/Archives/edgar/data/1285819/000143774926010636/omer20251231_10k.htm
- 10-Q filed Aug 12, 2026: https://www.sec.gov/Archives/edgar/data/1285819/000143774926027318/omer20260630_10q.htm
- DEF 14A filed Apr 30, 2026: https://www.sec.gov/Archives/edgar/data/1285819/000155278126000281/e26114_omer-def14a.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/